Clinical Practice Guidelines for Chronic Kidney Disease in Adults: Part I. Definition, Disease Stages, Evaluation, Treatment, and Risk Factors

CYNDA ANN JOHNSON, M.D., M.B.A., Brody School of Medicine at East Carolina University, Greenville, North Carolina
ANDREW S. LEVEY, M.D., Tufts University School of Medicine, Boston, Massachusetts
JOSEF CORESH, M.D., PH.D., Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
ADEERA LEVIN, M.D., University of British Columbia Faculty of Medicine, Vancouver, British Columbia
JOSEPH LAU, M.D., Tufts-New England Medical Center, Boston, Massachusetts
GARABED EKNOYAN, M.D., Baylor College of Medicine, Houston, Texas

In February 2002, the Kidney Disease Outcome Quality Initiative of the National Kidney Foundation published clinical practice guidelines on chronic kidney disease. The first six of the 15 guidelines are of the greatest relevance to family physicians. Part I of this two-part article reviews guidelines 1, 2, and 3. Chronic kidney disease is defined by the presence of a marker of kidney damage, such as proteinuria (ratio of greater than 30 mg of albumin to 1 g of creatinine on untimed [spot] urine testing), or a decreased glomerular filtration rate for three or more months. Disease staging is based on the glomerular filtration rate. Evaluation should be directed at determining the type and severity of chronic kidney disease. Treatment goals include preventing disease progression and complications. The guidelines place special emphasis on the prevention and treatment of cardiovascular disease in patients with chronic kidney disease. Risk factors for chronic kidney disease include diabetes mellitus, hypertension, family history of chronic kidney disease, age older than 60 years, and U.S. racial or ethnic minority status. The guidelines recommend testing for proteinuria and estimating the glomerular filtration rate in patients at risk for chronic kidney disease. Family physicians should weigh the value of the National Kidney Foundation guidelines for their clinical practice based on the strength of evidence and perceived cost-effectiveness until additional evidence becomes available on the usefulness of the recommended quality indicators. (Am Fam Physician 2004;70:869-76. Copyright© 2004 American Academy of Family Physicians.)

Chronic kidney disease is a major public health problem throughout the world. In the United States, kidney failure is becoming increasingly common and is associated with poor health outcomes and high medical expenditures. In this country, the number of patients treated with dialysis or transplantation is projected to increase from 340,000 in 1999 to 651,000 in 2010.¹

The major outcomes of chronic kidney disease, regardless of the specific diagnosis (i.e., type of kidney disease), include progression to kidney failure, complications from decreased kidney function, and development of cardiovascular disease. Increasing evidence shows that early detection and treatment often can prevent or delay some of these adverse outcomes.² However, opportunities for prevention may be lost because chronic kidney disease is not diagnosed or is treated insufficiently.³-⁶ One reason is lack of agreement about the definition of chronic kidney disease, as well as the classification of its stages. Another reason is lack of uniform application of simple tests for the detection and evaluation of the disease.

In February 2002, the Kidney Disease Outcome Quality Initiative of the National Kidney Foundation published clinical practice guidelines on chronic kidney disease. The first six of the 15 guidelines are of the greatest relevance to family physicians. Part I of this two-part article reviews guidelines 1, 2, and 3. Chronic kidney disease is defined by the presence of a marker of kidney damage, such as proteinuria (ratio of greater than 30 mg of albumin to 1 g of creatinine on untimed [spot] urine testing), or a decreased glomerular filtration rate for three or more months. Disease staging is based on the glomerular filtration rate. Evaluation should be directed at determining the type and severity of chronic kidney disease. Treatment goals include preventing disease progression and complications. The guidelines place special emphasis on the prevention and treatment of cardiovascular disease in patients with chronic kidney disease. Risk factors for chronic kidney disease include diabetes mellitus, hypertension, family history of chronic kidney disease, age older than 60 years, and U.S. racial or ethnic minority status. The guidelines recommend testing for proteinuria and estimating the glomerular filtration rate in patients at risk for chronic kidney disease. Family physicians should weigh the value of the National Kidney Foundation guidelines for their clinical practice based on the strength of evidence and perceived cost-effectiveness until additional evidence becomes available on the usefulness of the recommended quality indicators. (Am Fam Physician 2004;70:869-76. Copyright© 2004 American Academy of Family Physicians.)

© See editorial on page 823.
© This is part I of a two-part article on chronic kidney disease. Part II, “Glomerular Filtration Rate, Proteinuria, and Other Markers,” will appear in the next issue of AFP.
See page 801 for definitions of strength-of-recommendation labels.
AFP This article exemplifies the AAFP Annual Clinical Focus on caring for America’s aging population.
Early detection and treatment often can prevent or delay some adverse outcomes of chronic kidney disease.

The Authors

CYNDA ANN JOHNSON, M.D., M.B.A., is dean of the Brody School of Medicine at East Carolina University, Greenville, N.C. Previously she was professor and head of the Department of Family Medicine at the University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City. Dr. Johnson is a past president of the American Board of Family Practice. She also is the co-author of Women’s Health Care Handbook.

ANDREW S. LEVEY, M.D., is the Dr. Gerald J. and Dorothy R. Friedman professor of medicine at Tufts University School of Medicine, Boston, and chief of the William B. Schwartz, M.D., Division of Nephrology at Tufts-New England Medical Center, Boston. Dr. Levey is past chair of the National Kidney Foundation (NKF) Task Force on Cardiovascular Disease in Chronic Renal Disease and chair of the NKF Work Group on Hypertension and Antihypertensive Agents in Chronic Kidney Disease.

JOSEF CORESH, M.D., PH.D., is associate professor of epidemiology, medicine, and biostatistics at Johns Hopkins Bloomberg School of Public Health, Baltimore. Dr. Coresh serves on the National Analgesic Nephropathy Advisory Committee and is conducting research on cardiovascular and kidney diseases. He is an American Heart Association established investigator.

ADEERA LEVIN, M.D., is clinical associate professor of nephrology, director of clinical research and education for nephrology, and postgraduate fellowship director at the University of British Columbia Faculty of Medicine, Vancouver. Dr. Levin is a past president of the Canadian Society of Nephrology. She is on the editorial boards of Nephrology Dialysis Transplantation and the American Journal of Kidney Disease.

JOSEPH LAU, M.D., is professor of medicine and professor of clinical research for the Division of Clinical Care Research at Tufts-New England Medical Center. He currently is director of one of the Agency for Health Care Research and Quality’s evidence-based practice centers, as well as director of the Boston branch of the U.S. Cochrane Center. Dr. Lau also serves as methodologic director of the NKF K/DOQI evidence-based clinical practice guidelines program. He is a member of the editorial board of Clinical Evidence.

GARABED EKNOYAN, M.D., is professor of medicine at Baylor College of Medicine, Houston, and co-chair of the NKF Kidney Disease Outcomes Quality Initiative. Dr. Eknayan is a past president of the NKF. He currently serves on the editorial boards of Clinical Nephrology, Advances in Renal Replacement Therapy, and Seminars in Nephrology.

Address correspondence to Cynda Ann Johnson, M.D., M.B.A., Dean, Brody School of Medicine at East Carolina University, 600 Moye Blvd., Suite AD-52, Greenville, NC 27834 (e-mail: johnsoncyn@mail.ecu.edu). Reprints are not available from the authors.

Outcome Quality Initiative (K/DOQI) of the National Kidney Foundation (NKF) published clinical practice guidelines on chronic kidney disease. The goals of the Work Group that developed the guidelines were as follows: to define chronic kidney disease and classify its stages, regardless of the underlying cause; to evaluate laboratory measurements for clinical assessment of kidney disease; to associate the level of kidney function with the complications of chronic kidney disease; and to stratify risk for the loss of kidney function and the development of cardiovascular disease.

The leaders of the NKF recognized the role of family physicians in providing medical care for patients with chronic kidney disease (particularly during the early stages when interventions might slow disease progression) and therefore wanted the guidelines to be practical and accessible to primary care physicians. To these ends, a family physician was invited to be an active participant in the guidelines Work Group and a member of the K/DOQI Advisory Board, which oversees all guidelines developed under its auspices. At present, there are only about 5,000 nephrologists in the United States. With the projected increase in the number of patients diagnosed with chronic kidney disease (especially as defined by the NKF guidelines), a strong partnership with family physicians and general internists will be necessary.

The first purpose of this article is to disseminate the simple definition and the five-stage classification system of chronic kidney disease that were developed through an evidence-based process and justified with existing literature. The second purpose is to describe the six guidelines with the most immediate relevance to family physicians. Guidelines on evaluation, treatment, and risk factors are reviewed in part I of this two-part article. Part II reviews guidelines on estimation of glomerular filtration rate, assessment of proteinuria, and use of markers of chronic kidney disease other than proteinuria.

Background

The NKF Work Group defined two principal outcomes of chronic kidney disease: progressive loss of kidney function and development of complications, particularly cardiovascular disease.

Progressive loss of kidney function over time in most patients with chronic kidney disease is a well-known outcome. Because of the older age at onset for many forms of kidney disease and the slow rate of decline in kidney function, decreased kidney function
Chronic Kidney Disease

is far more common than kidney failure, for which replacement therapy (dialysis or transplantation) becomes necessary.

 Decreased kidney function is associated with complications in virtually all organ systems. Therapeutic interventions in the earlier stages may prevent or ameliorate some of these complications, as well as slow progression to kidney failure. Cardiovascular disease is considered an outcome of chronic kidney disease for several reasons. First, cardiovascular events are more common than kidney failure in patients with chronic kidney disease. In addition, chronic kidney disease appears to be a risk factor for cardiovascular disease.

 Cardiovascular disease in patients with chronic kidney disease is treatable, as well as potentially preventable. A 1998 report from the NKF Task Force on Cardiovascular Disease10 recommended that patients with chronic kidney disease be considered in the “highest risk” group for subsequent cardiovascular events, and that most interventions that are effective in the general population should be applied to patients with chronic kidney disease.11,12

 Guideline 1: Definition and Stages of Chronic Kidney Disease

Early detection and treatment often can prevent or delay adverse outcomes in patients with chronic kidney disease. Routine laboratory tests can detect the disease in its earlier stages (NKF grades R and O).7

A definition of chronic kidney disease is provided in Table 2.7 The presence of the disease should be established based on the occurrence of kidney damage and the level of kidney function (i.e., glomerular filtration rate [GFR]), regardless of the specific diagnosis. Disease stage should be assigned based on the level of kidney

<p>| TABLE 1 |
| Grading of Rationale Statements in the NKF Clinical Practice Guidelines for Chronic Kidney Disease |</p>
<table>
<thead>
<tr>
<th>Grade</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>Analysis of individual patient data from a single, large, generalizable study of high methodologic quality (e.g., NHANES III)</td>
</tr>
<tr>
<td>C</td>
<td>Compilation of original articles (using evidence tables)</td>
</tr>
<tr>
<td>R</td>
<td>Review of reviews and selected original articles</td>
</tr>
<tr>
<td>O</td>
<td>Opinion</td>
</tr>
</tbody>
</table>

NKF = National Kidney Foundation; NHANES III = Third National Health and Nutrition Examination Survey.

| TABLE 2 |
| NKF Definition of Chronic Kidney Disease |

Kidney damage for three or more months, as defined by structural or functional abnormalities of the kidney, with or without decreased GFR, manifested by pathologic abnormalities or markers of kidney damage, including abnormalities in the composition of the blood or urine or abnormalities in imaging tests

GFR < 60 mL per minute per 1.73 m² for three months or more, with or without kidney damage

NKF = National Kidney Foundation; GFR = glomerular filtration rate.
Kidney damage usually is ascertained by the presence or absence of certain markers, rather than by kidney biopsy. The NKF guidelines\textsuperscript{7,8} emphasize persistent proteinuria as a marker of kidney damage, because proteinuria has been studied most thoroughly\textsuperscript{13} and is identified readily using a simple office procedure. A ratio of greater than 30 mg of albumin to 1 g of creatinine in an untimed (spot) urine sample usually is considered abnormal. Other markers of kidney damage include abnormalities in urine sediment, blood, and urine chemistries, and abnormal findings on imaging studies. Patients who have normal kidney function but have markers of kidney damage are at increased risk for adverse outcomes of chronic kidney disease.

The GFR is considered the best measure of overall kidney function.\textsuperscript{14} Normal GFR varies according to patient age, sex, and body size. In young adults, the normal GFR is approximately 120 to 130 mL per minute per 1.73 m\textsuperscript{2} and declines with age.\textsuperscript{14-17} A GFR level below 60 mL per minute per 1.73 m\textsuperscript{2} represents loss of one half or more of the adult level of normal kidney function. Traditionally, an age-related decline in GFR has been considered “normal.” However, a decreased GFR in an elderly patient requires adjustment of drug dosages\textsuperscript{18} and appears to be an independent predictor of adverse outcomes such as mortality and cardiovascular disease.\textsuperscript{19-21}

The definition of chronic kidney disease is not modified based on patient age. The situation is analogous to the situation with blood pressure levels and the definition and prevalence of hypertension. Blood pressure rises with age, but hypertension in elderly persons is associated with adverse outcomes; however, the definition of hypertension is not age dependent, and the majority of elderly persons are classified as having hypertension.\textsuperscript{22} Similarly, because of the age-related decline in GFR, the prevalence of chronic kidney disease increases with age; approximately 17 percent of persons older than 60 years have an estimated GFR of less than 60 mL per minute per 1.73 m\textsuperscript{2}.\textsuperscript{6}

Kidney failure is defined as a GFR below 15 mL per minute per 1.73 m\textsuperscript{2}, usually accompanied by signs and symptoms of uremia, or as the need for initiation of kidney replacement therapy for management of the complications of a decreased GFR. In the United States, approximately 98 percent of patients begin dialysis when their GFR falls below 15 mL per minute per 1.73 m\textsuperscript{2}.\textsuperscript{23}

Kidney failure is not synonymous with end-stage renal disease (ESRD). In the United States, “end-stage renal disease” is an administrative term based on the conditions for health care payment by the Medicare ESRD Program for patients treated with dialysis or transplantation. However, the term does not include patients with kidney failure who are not treated with dialysis or transplantation. Thus, although the term “end-stage renal disease” is in widespread use and provides a simple operational classification of patients according to treatment, it does not precisely define a stage of severity in kidney disease.

As demonstrated in Table 3,\textsuperscript{5,7,24-26} more than 20 million adults in the United States have chronic kidney disease, and millions more are at risk of developing the disease. Patients who have diabetes mellitus and hypertension are at highest risk. As the number of patients with diabetes and hypertension continues to increase, the number of patients with chronic kidney disease also will increase. Consequently, clear definition and classification of the stages of disease severity are needed to assess patients for the development and progression of chronic kidney disease.

The stage of chronic kidney disease should be assigned based on the level of kidney function, regardless of the specific diagnosis.
answers. For example, at what stage does the nephrologist want to see a potential kidney transplant recipient? What interventions should be used at each stage to give a patient the best chance of preserving kidney function?

Staging of chronic kidney disease also allows physicians to talk more clearly with patients. For example, use of the word “kidney” rather than “renal” facilitates communication. In addition, patients are becoming accustomed to dealing with numbers (cholesterol levels, blood pressure measurements, blood sugar levels). Knowing their GFR and the type of personal interventions that may slow the decline in GFR allows patients to take greater control of their disease.

Guideline 2: Evaluation and Treatment of Chronic Kidney Disease

Patients with chronic kidney disease should be evaluated to determine the following: specific diagnosis (type of kidney disease), comorbid conditions, disease severity (assessed by the level of kidney function), complications (related to the level of kidney function), risk for loss of kidney function, and risk for development of cardiovascular disease (NKF grades R and O).7

Treatment of patients with chronic kidney disease includes the following: therapy based on the specific diagnosis, evaluation, and management of comorbid conditions; measures to slow loss of kidney function; measures to prevent and treat cardiovascular disease.

<table>
<thead>
<tr>
<th>TABLE 3</th>
<th>NKF Classification of Chronic Kidney Disease*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stage</strong></td>
<td><strong>Description‡</strong></td>
</tr>
<tr>
<td>—</td>
<td>At increased risk for chronic kidney disease</td>
</tr>
<tr>
<td>1</td>
<td>Kidney damage with normal or elevated GFR</td>
</tr>
<tr>
<td>2</td>
<td>Kidney damage with mildly decreased GFR</td>
</tr>
<tr>
<td>3</td>
<td>Moderately decreased GFR</td>
</tr>
<tr>
<td>4</td>
<td>Severely decreased GFR</td>
</tr>
<tr>
<td>5</td>
<td>Kidney failure</td>
</tr>
</tbody>
</table>

NKF = National Kidney Foundation; GFR = glomerular filtration rate.

*—Chronic kidney disease is defined as either kidney damage or a GFR below 60 mL per minute per 1.73 m² for three months or more. Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.

‡—For stages 1 and 2, kidney damage was estimated by a ratio of greater than 17 mg of albumin to 1 g of creatinine in men or greater than 25 mg of albumin to 1 g of creatinine in women on two untimed (spot) urine tests.

§—Includes actions from preceding stages.

||—Prevalence of persons at increased risk for chronic kidney disease has not been estimated accurately.

lar disease; measures to prevent and treat complications of decreased kidney function; preparation for kidney failure and kidney replacement therapy; and replacement of kidney function by dialysis or transplantation if signs and symptoms of uremia are present.

Medications should be reviewed at all visits. Dosage adjustments should be based on the level of kidney function. It is important to detect drug interactions, as well as potentially adverse effects of medications on kidney function or complications of chronic kidney disease. If possible, therapeutic drug monitoring should be performed.

A clinical action plan should be developed for each patient, with the plan based on the disease stage (Table 3).6,7,24-26 Self-management behaviors should be incorporated into the treatment plan at all stages of the disease.

Patients with chronic kidney disease should be referred to a nephrologist for consultation and co-management if a clinical action plan cannot be prepared, the appropriate evaluation cannot be performed, or the recommended treatment cannot be implemented. In most cases, patients with a GFR below 30 mL per minute per 1.73 m² should be referred to a nephrologist (NKF grade O).7

Diagnosis of chronic kidney disease traditionally is based on pathology and etiology. A simplified classification emphasizes diseases in the native kidneys (broadly divided into those that are diabetic or nondiabetic in origin) and kidney disease in the transplant patient. In the United States, diabetic kidney disease is the most common cause of kidney failure; its earliest manifestation is microalbuminuria with a normal or elevated GFR. Of note, the NKF guidelines7 classify patients who have diabetes and microalbuminuria with a normal GFR as having stage 1 chronic kidney disease. Nondiabetic kidney disease includes glomerular, vascular, tubulointerstitial, and cystic kidney diseases.

Specific treatment depends on the diagnosis, and a thorough search for “reversible causes” of kidney disease should be conducted. The remainder of the action plan is based on the stage of chronic kidney disease, irrespective of the diagnosis (Table 3).6,7,24-26

**Guideline 3: Risk Factors for Chronic Kidney Disease**

The risk of developing chronic kidney disease is increased in some patients without kidney damage and with a normal or elevated GFR (NKF grade R).7 During the routine health care visit, all patients should be assessed for increased risk based on clinical and sociodemographic factors (Table 4).7

Patients determined to be at increased risk for kidney disease should undergo testing for markers of kidney damage and an estimation of their GFR. Patients found to have chronic kidney disease should be evaluated and treated as specified in NKF guideline 2. Patients at increased risk who are found not to have chronic kidney disease should be advised to follow a program

### Table 4

<table>
<thead>
<tr>
<th>Type</th>
<th>Definition</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Susceptibility</td>
<td>Factors that increase susceptibility to kidney damage</td>
<td>Older age, family history of chronic kidney disease, reduction in kidney mass, low birth weight, U.S. racial or ethnic minority status, low income or educational level</td>
</tr>
<tr>
<td>Initiation factors</td>
<td>Factors that directly initiate kidney damage</td>
<td>Diabetes mellitus, high blood pressure, autoimmune diseases, systemic infections, urinary tract infections, urinary stones, obstruction of lower urinary tract, drug toxicity</td>
</tr>
<tr>
<td>Progression factors</td>
<td>Factors that cause worsening kidney damage and faster decline in kidney function after kidney damage has started</td>
<td>Higher level of proteinuria, higher blood pressure level, poor glycemic control in diabetes, smoking</td>
</tr>
<tr>
<td>End-stage factors</td>
<td>Factors that increase morbidity and mortality in kidney failure</td>
<td>Lower dialysis dose (Kt/V),* temporary vascular access, anemia, low serum albumin level, late referral for dialysis</td>
</tr>
</tbody>
</table>

*—In Kt/V (accepted nomenclature for dialysis dose), “K” represents urea clearance, “t” represents time, and “V” represents volume of distribution for urea.

of risk factor reduction (if appropriate) and should be reevaluated periodically.

During the routine health care visit, patients should be asked specifically about clinical and sociodemographic factors that have been implicated as susceptibility or initiation factors for chronic kidney disease. If any of these factors are present, patients should be assessed for albuminuria, and GFR should be estimated. The prevalence of persons at increased risk for chronic kidney disease has not been determined. However, the number of these persons is likely to far exceed the number of patients with the disease. Particular emphasis should be given to patients with diabetes mellitus, hypertension, family history of chronic kidney disease, age older than 60 years, and U.S. racial or ethnic minority status.

Guideline 3 is problematic for family physicians who have the task of identifying patients at risk for kidney disease. In preparing the NKF guideline, the Work Group evaluated evidence for the definition, classification, and prevalence of risk factors (NKF grade R). However, the issue of universal testing for kidney disease or testing of patients at increased risk for kidney disease has not been studied systematically. In the United States, testing currently is not recommended, except in patients with hypertension, diabetes, or known kidney disease.

Based on personal opinion and experience, the Work Group members recommend testing of patients who are at increased risk for kidney disease. In fact, a focus of the public awareness campaign stemming from the NKF guidelines is to encourage patients who think they may be at increased risk to tell their physician, and for the physician to test at-risk patients for albuminuria and GFR. Nonetheless, more research is needed to clearly identify the risks and benefits (both clinical and economic) of testing large segments of the U.S. population.

The authors indicate that they do not have any conflicts of interest. Sources of funding: AstraZeneca Pharmaceuticals LP is the primary sponsor of the NKF K/DOQI guidelines, Merck & Co., Inc. is the implementation sponsor, and Amgen Inc. is the founding and principal sponsor of K/DOQI.

The authors acknowledge the contributions of other members of the NKF K/DOQI Work Group and Evidence Review Team, the K/DOQI Support Group and Advisory Board, and the National Kidney Foundation.

**REFERENCES**

Chronic Kidney Disease


15. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow and tubular excre-


